Abbott Laboratories (ABT)

62.14
0.20 0.32
NYSE : Health Technology
Prev Close 62.34
Open 62.39
Day Low/High 62.04 / 62.49
52 Wk Low/High 47.83 / 64.60
Volume 5.11M
Avg Volume 5.59M
Exchange NYSE
Shares Outstanding 1.75B
Market Cap 110.14B
EPS 0.30
P/E Ratio 299.14
Div & Yield 1.12 (1.73%)

Latest News

How to Handle the Fed: Cramer's 'Mad Money' Recap (Wednesday 6/13/18)

How to Handle the Fed: Cramer's 'Mad Money' Recap (Wednesday 6/13/18)

Jim Cramer says higher rates always trigger rotations. Here's what investors should expect.

Weekly Roundup

Markets bathed in the afterglow of the strong jobs report for most of the week.

Abbott Declares 378th Consecutive Quarterly Dividend

Abbott Declares 378th Consecutive Quarterly Dividend

ABBOTT PARK, Ill., June 8, 2018 /PRNewswire/ -- The board of directors of Abbott (NYSE: ABT) today declared a quarterly common dividend of 28 cents per share.

100 Stocks That Could Change Your Financial Future

100 Stocks That Could Change Your Financial Future

Looking for good stock ideas? TheStreet has you covered with a plethora of names gleaned from our readings.

Weekly Roundup

Markets go through a short and volatile week.

Abbott Introduces The Afinion™ 2 Analyzer Rapid Test System For Diabetes Management

STATE-OF-THE-ART MULTI-ASSAY TEST SYSTEM HELPS PEOPLE WITH DIABETES GET THE HbA1c RESULTS THEY NEED WITHIN 3 MINUTES -- ALLOWING MORE TIME FOR CONSULTATION AND CARE DURING A SINGLE HEALTHCARE VISIT

Jim Cramer's List of 88 Stocks to Watch With Interest Rates Falling Again

Jim Cramer's List of 88 Stocks to Watch With Interest Rates Falling Again

The Memorial Day holiday is now over, and it's time for investors to get back to work looking for top stocks. TheStreet's founder Jim Cramer has a must watch list.

Medical Device Stocks Could Be Gearing Up to Be Market Leaders

Medical Device Stocks Could Be Gearing Up to Be Market Leaders

When chartists look for the next market leaders they often go to stocks that have held up the best during corrections.

Jim Cramer: When Rates Decline, 96% of the S&P 500 Benefits

Jim Cramer: When Rates Decline, 96% of the S&P 500 Benefits

When rates decline, most of the S&P 500 benefits, according to TheStreet's founder and Action Alerts PLUS Portfolio Manager Jim Cramer.

Jim Cramer: Stocks That Do Well In a Declining Rate Environment Are Back

Jim Cramer: Stocks That Do Well In a Declining Rate Environment Are Back

The crash of oil will only accelerate the move.

Weekly Roundup

China trade wars, North Korea tensions and oil volatility hit the markets this week.

Abbott Laboratories Takes Over #38 Spot From NextEra Energy

In a study of analyst recommendations at the major brokerages, for the underlying components of the S&P 500, Abbott Laboratories has taken over the #38 spot from NextEra Energy Inc , according to ETF Channel. Below is a chart of Abbott Laboratories versus NextEra Energy Inc plotting their respective rank within the S&P 500 over time (ABT plotted in blue; NEE plotted in green): In forming the rank, the analyst opinions from the major brokerage houses were tallied, and averaged; then, the underlying components were ranked according to those averages.

Newest Generation Of Leading Heart Stent Is Now Approved In The U.S. For People With Coronary Artery Disease

- XIENCE Sierra™, the newest generation of XIENCE drug-eluting stents, received U.S. Food and Drug Administration (FDA) approval

Abbott's Investigational Tendyne™ Device For Mitral Valve Replacement Demonstrates Positive Outcomes At 30 Days In Global Study

- Promising results for Tendyne valve presented as late-breaking clinical trial at EuroPCR

Updates on Honeywell, Abbot and Nvidia

Conference highlights from Honeywell bolster the investment case.

Five-Year Study Data Confirm Positive Outcomes For Patients When Abbott Diagnostic Tool Was Used To Guide Heart Stenting Decisions

- Late-breaking data presented at EuroPCR and simultaneously published in "The New England Journal of Medicine" support use of Abbott's PressureWire™ guidewire to help physicians make stenting decisions

Weekly Roundup

Markets consolidate after recent gains

Jim's Daily Rundown

Jim discusses Macy's quarter as a readthrough to Nordstrom, defense and North Korea, and more on the market!

Being Bullish on Trump Surprisingly Worked Well for Investors This Week

Being Bullish on Trump Surprisingly Worked Well for Investors This Week

President Trump reduced tensions in Korea, raised them in the Middle East, and mainly relieved them for investors in the drug and healthcare industries.

Weekly Roundup

The markets strongly rebounded this week as a few of the major averages pushed into positive year-to-date territory.

Weekly Roundup

A strong Friday failed to keep markets in positive territory.

Abbott Expands Cardiac Arrhythmias Portfolio With FDA Clearance Of Advanced Mapping Catheter

- ADVISOR™ HD GRID MAPPING CATHETER, SENSOR ENABLED™ FACILITATES IMPROVED DATA COLLECTION, SUPPORTING OPTIMAL TREATMENT FOR PATIENTS WITH COMPLEX CARDIAC ARRHYTHMIAS

Abbott's XIENCE Sierra™ Heart Stent Receives National Reimbursement In Japan To Treat People With Coronary Artery Disease

- Provides patients with access to latest-generation gold-standard heart stent through Japan's health insurance system

Weekly Roundup

Markets end flat for week as strong earnings fail to excite investors.

Four Additions and One Removal From the Bullpen

On a rough day for markets we review new additions to our investing bullpen.

Sanquin Selects Abbott's "Alinity™ S" Solution For Blood And Plasma Screening

LONG-TERM AGREEMENT BETWEEN SANQUIN, A LEADER IN BLOOD SERVICES, AND ABBOTT, A GLOBAL LEADER IN TRANSFUSION MEDICINE, HELPS ENSURE A SAFE AND EFFICIENT BLOOD SUPPLY IN THE NETHERLANDS

Weekly Roundup

Markets give up some gains Thursday and Friday, ahead of heavy earnings next week.

TheStreet Quant Rating: B- (Buy)